Safety and efficacy of mFOLFOX6+panitumumab combination therapy and 5-FU/LV + panitumumab combination therapy in patients with chemotherapy-naive metastatic colorectal cancer (SAPPHIRE)

被引：0
|
作者：
Nagata, N. [1 ]
Mishima, H. [2 ]
Kurosawa, S. [3 ]
Oba, K. [4 ]
Sakamoto, J. [5 ]
机构：
[1] Kitakyushu Gen Hosp, Surg, Kitakyushu, Fukuoka, Japan
[2] Aichi Med Univ, Clin Oncol, Nagakute, Aichi 48011, Japan
[3] Takeda Pharmaceut Co Ltd, GMA J, Tokyo, Japan
[4] Univ Tokyo, Grad Sch Med, Sch Publ Hlth, Biostat, Tokyo, Japan
[5] Tokai Cent Hosp, Kakamigahara, Japan
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
228TiP
引用
收藏
页码：68 / 68
页数：1
相关论文
共 50 条
  • [31] Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer
    Toshi Takaoka
    Tetsuo Kimura
    Rai Shimoyama
    Shunji Kawamoto
    Kazuki Sakamoto
    Fuminori Goda
    Hiroshi Miyamoto
    Yuji Negoro
    Akihito Tsuji
    Koji Yoshizaki
    Takahiro Goji
    Shinji Kitamura
    Hiromi Yano
    Koichi Okamoto
    Masako Kimura
    Toshiya Okahisa
    Naoki Muguruma
    Yoshiro Niitsu
    Tetsuji Takayama
    Cancer Chemotherapy and Pharmacology, 2016, 78 : 397 - 403
  • [32] Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer
    Takaoka, Toshi
    Kimura, Tetsuo
    Shimoyama, Rai
    Kawamoto, Shunji
    Sakamoto, Kazuki
    Goda, Fuminori
    Miyamoto, Hiroshi
    Negoro, Yuji
    Tsuji, Akihito
    Yoshizaki, Koji
    Goji, Takahiro
    Kitamura, Shinji
    Yano, Hiromi
    Okamoto, Koichi
    Kimura, Masako
    Okahisa, Toshiya
    Muguruma, Naoki
    Niitsu, Yoshiro
    Takayama, Tetsuji
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (02) : 397 - 403
  • [33] Panitumumab monotherapy compared with cetuximab and irinotecan combination therapy in patients with previously treated KRAS wild-type metastatic colorectal cancer
    Kennecke, H.
    Chen, L.
    Blanke, C. D.
    Cheung, W. Y.
    Schaff, K.
    Speers, C.
    CURRENT ONCOLOGY, 2013, 20 (06) : 326 - 332
  • [34] Pilot study of vemurafenib and panitumumab combination therapy in patients with BRAF V600E mutated metastatic colorectal cancer.
    Yaeger, Rona D.
    Cercek, Andrea
    O'Reilly, Eileen Mary
    Reidy, Diane Lauren
    Kemeny, Nancy E.
    Wolinsky, Tamar
    Gollub, Marc J.
    Lacouture, Mario E.
    Rosen, Neal
    Vakiani, Efsevia
    Saltz, Leonard
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [35] Combination of oxaliplatin (OXA) and 5-fluorouracil, leucovorin (5-FU/LV), as first line therapy, in elderly patients >70years, with metastatic colorectal cancer.
    Botto, HG
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 298S - 298S
  • [36] Efficacy and safety of bevacizumab-based combination therapy for treatment of patients with metastatic colorectal cancer
    Xu, Ran
    Xu, Chen
    Liu, Chuntong
    Cui, Can
    Zhu, Jing
    ONCOTARGETS AND THERAPY, 2018, 11 : 8605 - 8621
  • [37] Combination therapy with infusional 5-FU and 'Tomudex' for patients (pts) with advanced colorectal cancer - A phase I study
    Harstrick, A
    Mayer, S
    Hilger, R
    Muller, C
    Dohmen, D
    Kloppel, R
    Vanhoefer, U
    Scheulen, ME
    Wilke, H
    Seeber, S
    ANNALS OF ONCOLOGY, 1998, 9 : 35 - 36
  • [38] Panitumumab therapy with irinotecan, 5-fluorouracil, and leucovorin (IFL) in patients (pts) with metastatic colorectal cancer (mCRC)
    Berlin, Jordan
    Malik, Imtiaz
    Picus, Joel
    Glisson, Shawn
    Kozloff, Mark
    Spitzer, Gary
    Wiens, Brian
    MacDonald, Monica
    Jerian, Susan
    Hecht, J. Randolph
    ANNALS OF ONCOLOGY, 2004, 15 : 70 - 71
  • [39] First-line panitumumab versus bevacizumab in combination with mFOLFOX6 for RAS wild-type metastatic colorectal cancer: PARADIGM trial results
    Muro, K.
    Watanabe, J.
    Shitara, K.
    Yamazaki, K.
    Ohori, H.
    Shiozawa, M.
    Yasui, H.
    Oki, E.
    Sato, T.
    Naitoh, T.
    Komatsu, Y.
    Kato, T.
    Hihara, M.
    Soeda, J.
    Yamamoto, K.
    Akagi, K.
    Ochiai, A.
    Uetake, H.
    Yoshino, T.
    ANNALS OF ONCOLOGY, 2022, 33 : S377 - S377
  • [40] TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer
    Borelli, Beatrice
    Moretto, Roberto
    Lonardi, Sara
    Bonetti, Andrea
    Antoniotti, Carlotta
    Pietrantonio, Filippo
    Masi, Gianluca
    Burgio, Valentina
    Marmorino, Federica
    Salvatore, Lisa
    Rossini, Daniele
    Zaniboni, Alberto
    Zucchelli, Gemma
    Martignetti, Angelo
    Di Battista, Monica
    Pella, Nicoletta
    Passardi, Alessandro
    Boccaccino, Alessandra
    Leone, Francesco
    Colombo, Camilla
    Granetto, Cristina
    Vannini, Francesca
    Marsico, Valentina Angela
    Martinelli, Erika
    Antonuzzo, Lorenzo
    Vitello, Stefano
    Delliponti, Laura
    Boni, Luca
    Cremolini, Chiara
    Falcone, Alfredo
    ESMO OPEN, 2018, 3 (04)
12345